According to a pan-cancer analysis, the amount of KEAP1 mutations in 40,167 patients with distinct cancer types was 2.7%; patients with NSCLC had the highest levels of KEAP1 mutations (15.8%) (120). Here, KEAP1 is linked to cancer.